FOXD1 upregulates DARS2-mediated glycolysis to drive cisplatin resistance in bladder cancer. Li X, Su M, Luo J, Han D, et al. Urol Oncol 2026 Sep 5:S1078-1439(26)00619-8. doi: 10.1016/j.urolonc.2026.

Read + Share

Amedeo Smart

Independent Medical Education

Li X, Su M, Luo J, Han D, et al. FOXD1 upregulates DARS2-mediated glycolysis to drive cisplatin resistance in bladder cancer. Urol Oncol 2026 Sep 5:S1078-1439(26)00619-8. doi: 10.1016/j.urolonc.2026.
PMID: 42701051